A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS,AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
Primary Objective
To evaluate the safety and select the RP2D of CELMoDs (CC-220 and CC-99282) in combination with mosunetuzumab SC in Cohort A1, Cohort A2, Cohort B1,and Cohort B. To evaluate the safety and select the RP2D of CELMoDs (CC-220 and CC-99282) in combination with glofitamab IV in Cohort C1, Cohort C2, Cohort D1, and Cohort D2
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Manali Kamdar, MD
Study ID
Protocol Number: 22-0939
More information available at ClinicalTrials.gov: NCT05169515
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers